Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ProMedex DTC Antihistamine Counterdetail Aims To Enroll 3,000 in 60 Days

Executive Summary

ProMedex' Symptom-Free allergy program to counter DTC-stimulated demand for antihistamines plans to enroll 3,000 patients with allergic rhinitis in the first two months.

You may also be interested in...



P&U Detrol Patient Compliance Program Discussed With MCOs In Phase II

Pharmacia & Upjohn's patient compliance program for its urinary incontinence drug Detrol was discussed with managed care early in the product's development, former P&U Direct-to-Consumer Product Manager Bruce Houtman told a Strategic Research Institute DTC Rx Marketing and Advertising Conference in New York City June 29.

Managed Care Is Moving Toward Restricting DTC Advertised Drugs - Cigna VP

Restrictions on direct-to-consumer advertised drugs are being considered by managed care organizations in order to control increasing costs driven by patient demand, Cigna Healthcare VP Peter Penna told an Institute for International Research conference Sept. 15.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel